Literature DB >> 20356072

Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.

Umesh M Hanumegowda1, Gottfried Wenke, Alicia Regueiro-Ren, Roumyana Yordanova, John P Corradi, Stephen P Adams.   

Abstract

Drug-induced phospholipidosis (PLD) is an adaptive histologic alteration that is seen with various marketed drugs and often encountered during drug development. Various in silico and in vitro cell-based methods have been developed to predict the PLD-inducing potential of compounds. These methods rely on the inherent physicochemical properties of the molecule and, as such, tend to overpredict compounds as PLD inducers. Recognizing that the distribution of compounds into tissues or tissue accumulation is likely a key factor in PLD induction, in addition to key physicochemical properties, we developed a model to predict PLD in vivo using the measures of basicity (pK(a)), lipophilicity (ClogP), and volume of distribution (V(d)). Using sets of PLD inducers and noninducers, we demonstrate improved concordance with this method. Furthermore, we propose a screening paradigm that includes a combination of various methods to predict the in vivo PLD-inducing potential of compounds, which may be especially useful in lead identification and optimization processes in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356072     DOI: 10.1021/tx9003825

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  10 in total

1.  Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.

Authors:  Sarah C McLeay; Peter Vis; Rolf P G van Heeswijk; Bruce Green
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  Second Generation Inhibitors of HIV-1 Maturation.

Authors:  Alicia Regueiro-Ren; Ira B Dicker; Umesh Hanumegowda; Nicholas A Meanwell
Journal:  ACS Med Chem Lett       Date:  2019-02-08       Impact factor: 4.345

3.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 4.  The significance of acid/base properties in drug discovery.

Authors:  David T Manallack; Richard J Prankerd; Elizabeth Yuriev; Tudor I Oprea; David K Chalmers
Journal:  Chem Soc Rev       Date:  2013-01-21       Impact factor: 54.564

Review 5.  Drug induced phospholipidosis: an acquired lysosomal storage disorder.

Authors:  James A Shayman; Akira Abe
Journal:  Biochim Biophys Acta       Date:  2012-08-30

6.  Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

Authors:  Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2013-02-01       Impact factor: 3.922

7.  Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system.

Authors:  Annapurna Pamreddy; Sooraj Baijnath; Tricia Naicker; Sphamandla Ntshangase; Sipho Mdanda; Hlengekile Lubanyana; Hendrik G Kruger; Thavendran Govender
Journal:  RSC Adv       Date:  2018-03-28       Impact factor: 4.036

8.  Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor.

Authors:  Jane C F Chang; Paul Ciaccio; Patricia Schroeder; Lindsay Wright; Russell Westwood; Anna-Lena Berg
Journal:  J Toxicol Pathol       Date:  2014-04-30       Impact factor: 1.628

9.  Identification of drugs inducing phospholipidosis by novel in vitro data.

Authors:  Markus Muehlbacher; Philipp Tripal; Florian Roas; Johannes Kornhuber
Journal:  ChemMedChem       Date:  2012-09-03       Impact factor: 3.466

10.  Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies.

Authors:  Linda R Barone; Scott Boyer; James R Damewood; James Fikes; Paul J Ciaccio
Journal:  J Toxicol       Date:  2012-06-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.